Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Entheon Biomedical Corp (ENTBF)

Entheon Biomedical Corp (ENTBF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ENTBF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0260 +30.77%
on 09/30/22
0.0720 -52.78%
on 09/02/22
-0.0155 (-31.31%)
since 08/30/22
3-Month
0.0260 +30.77%
on 09/30/22
0.0808 -57.92%
on 08/11/22
-0.0003 (-0.87%)
since 06/30/22
52-Week
0.0260 +30.77%
on 09/30/22
0.5715 -94.05%
on 11/08/21
-0.1760 (-83.81%)
since 09/30/21

Most Recent Stories

More News
Cybin (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate CYB004 Clinical Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 0.670 (+4.69%)
SILO : 5.38 (+3.96%)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
ATAI : 3.31 (+1.85%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
CMPS : 10.73 (-2.19%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

ENTBF : 0.0340 (-10.53%)
FTRP.TO : 1.09 (+5.83%)
SILO : 5.38 (+3.96%)
FTRP : 4.2105 (+1.07%)
ATAI : 3.31 (+1.85%)
CYBN : 0.4840 (+0.83%)
CMPS : 10.73 (-2.19%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited,...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned...

CYBN.NE : 0.670 (+4.69%)
CYBN : 0.4840 (+0.83%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in...

OTC.VN : 0.500 (unch)
EHVVF : 0.0064 (+6.67%)
ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference

Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming...

ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
Microdose Psychedelic Insights Presents the Upcoming DMT Conference, a Deep Dive Into the Dynamic Field of DMT Therapeutics

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights , a cutting-edge media company focused on promoting content, financial analysis, and engaging events...

ENBI.CN : 0.040 (-11.11%)
ENTBF : 0.0340 (-10.53%)
DMT.VN : 0.165 (+3.13%)
AGN.CN : 4.200 (unch)
AGNPF : 3.0300 (+0.33%)
Canadian Government Agency Removes Barrier for Psilocybin Therapy

Palm Beach, FL – December 16, 2020 – Health Canada, in a recent “breakthrough Exemption” has quietly expanded its list of who can legally possess and consume psilocybin-containing mushrooms...

PULL.CN : 0.020 (unch)
MYCO.CN : 0.400 (-6.98%)
RVVTF : 0.1740 (-8.42%)
RVV.CN : 0.235 (-9.62%)
LKYSF : 0.4800 (-3.63%)
NUMI.VN : 0.580 (+9.43%)
ENTBF : 0.0340 (-10.53%)
ENBI.CN : 0.040 (-11.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0447
2nd Resistance Point 0.0393
1st Resistance Point 0.0367
Last Price 0.0340
1st Support Level 0.0287
2nd Support Level 0.0233
3rd Support Level 0.0207

See More

52-Week High 0.5715
Fibonacci 61.8% 0.3631
Fibonacci 50% 0.2988
Fibonacci 38.2% 0.2344
Last Price 0.0340
52-Week Low 0.0260

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar